Literature DB >> 1419375

Oral tiludronate: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis.

J Y Reginster1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1419375     DOI： 10.1016/8756-3282(92)90450-b

Source DB:  PubMed          Journal:  Bone        ISSN： 1873-2763            Impact factor:   4.398


× No keyword cloud information.
  11 in total

Review 1.  Parathyroid hormone in the treatment of involutional osteoporosis: back to the future.

Authors:  J Y Reginster; A N Taquet; G Fraikin; C Gosset; B Zegels
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

2.  Assessment of a bone biopsy technique for measuring tiludronate in horses: a preliminary study.

Authors:  Catherine Delguste; Michèle Doucet; Annick Gabriel; Jérôme Guyonnet; Olivier M Lepage; Hélène Amory
Journal:  Can J Vet Res       Date:  2011-04       Impact factor: 1.310

3.  Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth.

Authors:  Marilena Tauro; Gemma Shay; Samer S Sansil; Antonio Laghezza; Paolo Tortorella; Anthony M Neuger; Hatem Soliman; Conor C Lynch
Journal:  Mol Cancer Ther       Date:  2017-01-09       Impact factor: 6.261

4.  A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone.

Authors:  W D Fraser; T C Stamp; R A Creek; J P Sawyer; C Picot
Journal:  Postgrad Med J       Date:  1997-08       Impact factor: 2.401

5.  Comparative study of potential for bisphosphonates to damage gastric mucosa of rats.

Authors:  C P Peter; M V Kindt; J A Majka
Journal:  Dig Dis Sci       Date:  1998-05       Impact factor: 3.199

6.  Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration.

Authors:  D Y Mitchell; W H Barr; R A Eusebio; K A Stevens; F P Duke; D A Russell; J D Nesbitt; J H Powell; G A Thompson
Journal:  Pharm Res       Date:  2001-02       Impact factor: 4.200

Review 7.  The role of bisphosphonates in the prevention and treatment of osteoporosis.

Authors:  J Y Reginster
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

8.  Serum kinetics, bioavailability and bone scanning of 99mTc-labelled sodium olpadronate in patients with different rates of bone turnover.

Authors:  O J Degrossi; M Ortiz; E B Degrossi; H García del Río; J C Barreira; D Messina; E Kerzberg; E J Roldán; E Montuori; A Pérez Lloret
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

9.  Effect of renal function on risedronate pharmacokinetics after a single oral dose.

Authors:  D Y Mitchell; J V St Peter; R A Eusebio; K A Pallone; S C Kelly; D A Russell; J D Nesbitt; G A Thompson; J H Powell
Journal:  Br J Clin Pharmacol       Date:  2000-03       Impact factor: 4.335

10.  Esophageal irritation due to alendronate sodium tablets: possible mechanisms.

Authors:  C P Peter; L K Handt; S M Smith
Journal:  Dig Dis Sci       Date:  1998-09       Impact factor: 3.199
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.